Pharmaceuticals

Newland

Newland released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 206.95 M, actual EPS CNY 0.0921

Newland to Release FY2026 Q1 Earnings on April 24 After-Market (BJT)

Newland released FY2025 Q4 earnings on March 19 After-Market (BJT), actual revenue CNY 191.14 M, actual EPS CNY 0.0755

Newland released FY2025 Annual Earnings on March 19 After-Market (BJT), Actual Revenue CNY 672.38 M, Actual EPS CNY 0.31

Newland FY2025 Annual Earnings Release on March 20, 2026 After-Market (BJT)

Newland released FY2025 Q3 earnings on October 21 After-Market BJT, actual revenue CNY 122.43 M, actual EPS CNY 0.035

Newland released FY2025 9 Months Earnings on October 21 After-Market (BJT), actual revenue CNY 481.24 M, actual EPS CNY 0.2351

Newland to Release FY2025 Q3 Earnings on October 22 After-Market (BJT)

Newland released FY2025 Q2 earnings on August 11 After-Market (BJT), actual revenue CNY 139.02 M, actual EPS CNY 0.0558

Newland released FY2025 Semi-Annual earnings on August 11 After-Market (BJT), actual revenue CNY 358.81 M, actual EPS CNY 0.2009

Newland FY2025 Semi-Annual Earning Release on August 12, 2025 (BJT)

Xintiandi's ESG Rating Dropped from BB to B

New Tian Di Clopidogrel Hydrogensulfate Raw Material Approved for Market

Investor Inquiry on XinTianDi's Tariff Impact

New Skyland's Q1 2025 Revenue Up 19.07% YoY

Newland released FY2025 Q1 earnings on April 21 After-Market BJT, actual revenue CNY 219.79 M, actual EPS CNY 0.1443

Newland FY2025 Q1 Earnings Release Scheduled for April 22 After-Market BJT

Newland released FY2024 annual earnings on March 10 After-Market (BJT), actual revenue CNY 726.44 M, actual EPS CNY 0.44

Newland released FY2024 Q4 earnings on March 10 After-Market (BJT), actual revenue CNY 189.19 M, actual EPS CNY 0.0791

Newland to Release FY2024 Annual Earnings on March 11 After-Market (BJT)

301277

Newland announced that the company recently signed a cooperation development and licensing agreement with Nanjing Zhihe Pharmaceutical Technology Co., Ltd. The two parties will carry out strategic cooperation in the field of GLP-1 class long-acting peptide innovative drugs. The cooperation includes drug research and development, production, commercialization, and external transactions. The signing of this agreement does not constitute a related party transaction, nor does it constitute a major asset reorganization, and it does not meet the review standards of the company's board of directors and shareholders' meeting. The agreement does not involve specific amounts and will not have a significant impact on the company's financial status, operating results, and performance for this year

Zhitong

Newland: Signed a cooperation agreement for GLP-1 class long-acting peptide innovative drugs

Newland released its Q3 2025 report, with operating revenue for the first three quarters at 481 million yuan, a year-on-year decrease of 10.42%; net profit attributable to the parent company was 91.907 million yuan, a year-on-year decline of 35.19%; net profit excluding non-recurring gains and losses was 83.6323 million yuan, a year-on-year decrease of 36.65%; basic earnings per share were 0.2344 yuan

Newland released its performance for the first three quarters, with a net profit attributable to the parent company of 91.907 million yuan, a decrease of 35.19%

Newland released its 2025 semi-annual performance, with revenue of 359 million yuan, a year-on-year decrease of 9.57%; net profit attributable to shareholders of the parent company was 78.03 million yuan, a year-on-year decrease of 30.01%; net profit excluding non-recurring items was 71.79 million yuan, a year-on-year decrease of 31.56%; basic earnings per share were 0.20 yuan. Despite the overall decline in performance, revenue from toluenesulfonic acid increased by 13.16% year-on-year, and the company has competitive advantages in the pharmaceutical and high-purity markets, actively expanding into high-end application fields

Newland released its semi-annual performance, with a net profit attributable to the parent company of 78.03 million yuan, a year-on-year decrease of 30.01%

Newland recently obtained the "Drug Registration Certificate" issued by the National Medical Products Administration, which pertains to the drug Vildagliptin tablets, suitable for the treatment of type 2 diabetes. Vildagliptin, as a selective DPP-4 inhibitor, can rapidly inhibit DPP-4 activity, increase endogenous GLP-1 and GIP levels, thereby enhancing β-cell sensitivity to glucose, promoting insulin secretion, and lowering blood glucose levels

Newland has obtained a drug registration certificate

002882

688336

301137

603607

Excluding newly listed stocks in the past year, a total of 23 stocks closed at historical highs today. From the perspective of industry attributes, stocks in the machinery equipment, pharmaceutical and biotechnology, and food and beverage industries are relatively concentrated at new highs, with 6, 5, and 2 stocks appearing on the list, respectively. Among the stocks that closed at historical highs, the average price increase today was 6.98%, with limit-up stocks including HIT WELDING, JLY Group, and ZHEJIANG JINGHUA LASER TECHNOLOGY. The top gainers included Sunshine Guojian Pharmaceutical, Changshan Pharmaceutical, and Newland

JLY Group

Sunshine Guojian Pharmaceutical

HIT WELDING

ZHEJIANG JINGHUA LASER TECHNOLOGY

CSBIO

23 stocks closed at a historic high

002094

002215

002549

300464

After-hours data shows that on May 27, a total of 35 stocks appeared on the leaderboard with institutional involvement, with 14 stocks showing net buying by institutions and 21 stocks showing net selling. The top three stocks with the highest net buying by institutions that day were KAIMEITE GASES, SACA, and Kingking, with net buying amounts of 47.93 million yuan, 34.13 million yuan, and 26.85 million yuan, respectively. The top three stocks with the highest net selling by institutions that day were Newland, Noposion, and Xinjinlu, with net outflow amounts of 47.62 million yuan, 41.72 million yuan, and 35.52 million yuan, respectively

Kingking

Noposion

KAIMEITE GASES

SACA

XINJINLU

Dragon and Tiger List | Institutions bought these 14 stocks today, sold Newland for 47.62 million yuan

Newland has received the notice of approval for the marketing application of the raw material drug clopidogrel hydrogen sulfate from the National Medical Products Administration, marking that the drug meets the drug review standards in China. Clopidogrel hydrogen sulfate is an antiplatelet drug primarily used for the prevention and treatment of cardiovascular and cerebrovascular diseases. This approval will enrich the company's product variety

Newland has obtained the approval notice for the marketing application of the raw material drug Clopidogrel Bisulfate

According to the Zhitong Finance APP, Newland released its first-quarter report for 2025, with operating revenue of 220 million yuan, a year-on-year increase of 19.07%. The net profit attributable to shareholders of the listed company was 56.5712 million yuan, a year-on-year increase of 1.17%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 52.4213 million yuan, a year-on-year increase of 0.29%. The basic earnings per share were 0.2 yuan

Newland released its first-quarter performance, with a net profit attributable to the parent company of 56.5712 million yuan, an increase of 1.17%

Newland released its 2024 annual report, with operating revenue of 726 million yuan, a year-on-year increase of 11.51%; net profit attributable to the parent company of 174 million yuan, a year-on-year increase of 9.22%; and earnings per share of 0.62 yuan. The company plans to distribute a cash dividend of 4 yuan for every 10 shares and to increase capital reserves by issuing 4 additional shares for every 10 shares to all shareholders. During the reporting period, the company strengthened internal management and focused on cost reduction and efficiency improvement

Newland released its 2024 annual performance, with a net profit attributable to the parent company of 174 million yuan, a year-on-year increase of 9.22%, and plans to distribute 4 yuan and issue 4 additional shares for every 10 shares

Newland has received the approval notice for the marketing application of Chlorpheniramine Maleate active pharmaceutical ingredient, indicating that the drug meets the technical standards for drug review in China and has been approved for domestic marketing. Chlorpheniramine Maleate is an antihistamine primarily used to treat allergic rhinitis and skin allergies, and it is expected to enrich the company's product variety

Newland has received the approval notice for the marketing application of Chlorpheniramine Maleate active pharmaceutical ingredient

Newland(301277.SZ)